A reduction in climate gas emissions by replacing the F-gas in asthma inhalers.
| Reference number | |
| Coordinator | Aer Beatha AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | November 2017 - May 2018 |
| Status | Completed |
| Venture | Innovative Startups |
Purpose and goal
The overall goal is to develop technology for asthma equipment and sell/license to pharmaceutical companies. The technology is expected to generate asthma products at lower costs. A further advantage of the technology is a significant reduction in environmental impact compared to current products. We have begun to involve strategic partners. The funding covered expenses related to the development and adaptation of methodology for the measurement of particle number and size distribution by applying the on-line state of the art technology for emissions and particle measurements.
Expected results and effects
The results show that carbon dioxide can be used as propellant gas instead of HFA134a. The prototype is capable of generating aerosol particles of the proper size distribution for use in the envisaged applications. We will use the project data to show that the concept works in the continuing dialogue with the pharmaceutical industry.
Planned approach and implementation
IVL has been a key partner in the testing phase and performed technical testing through the development of test protocols, testing according to test protocols and comparing data obtained by the standard method (Anderson Cascade Impactor) and (laser aerosol spectrometer) with the aim to develop a faster online method the characterization of size distribution. Further work is planned to involve representatives from the pharmaceutical industry and to develop and launch the appropriate paper spacer suitable for both day and inhalers to HFC-free inhaler.